The Incidence of Skin and Soft Tissue Infections in the United States and Associated Healthcare Utilization Between 2010 and 2020.

chronic ulcer epidemiology healthcare costs incidence skin and soft tissue infections

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Jun 2024
Historique:
received: 14 03 2024
accepted: 06 05 2024
medline: 5 6 2024
pubmed: 5 6 2024
entrez: 5 6 2024
Statut: epublish

Résumé

The number of patients with skin and soft tissue infections (SSTIs) in the United States appeared to be increasing well into the 21st century. However, no recent data have confirmed this trend. This retrospective, observational cohort study used claims data over 11 years (2010-2020) from Optum's de-identified Clinformatics Data Mart Database. SSTI episodes, complications, and comorbidities were identified using During the study period, 5.4 million patients experienced 9.1 million SSTI episodes, with an incidence of 77.5 (95% confidence interval, 77.4-77.5) per 1000 person-years of observation (PYO). Annual incidence did not change significantly over time. Overall incidence (per 1000 PYO) of SSTI episodes in patients without comorbidities was 32.1 (highest incidence was for previous SSTI [113.5]) versus much higher rates if comorbidities were present. Incidence rates (per 1000 PYO) of chronic ulcers increased over time from 11.3 to 18.2 ( The epidemiology of SSTI in the United States is changing and the disease burden is increasing despite stabilization in overall incidence. These data can inform identification of priority populations who could benefit from targeted interventions.

Sections du résumé

Background UNASSIGNED
The number of patients with skin and soft tissue infections (SSTIs) in the United States appeared to be increasing well into the 21st century. However, no recent data have confirmed this trend.
Methods UNASSIGNED
This retrospective, observational cohort study used claims data over 11 years (2010-2020) from Optum's de-identified Clinformatics Data Mart Database. SSTI episodes, complications, and comorbidities were identified using
Results UNASSIGNED
During the study period, 5.4 million patients experienced 9.1 million SSTI episodes, with an incidence of 77.5 (95% confidence interval, 77.4-77.5) per 1000 person-years of observation (PYO). Annual incidence did not change significantly over time. Overall incidence (per 1000 PYO) of SSTI episodes in patients without comorbidities was 32.1 (highest incidence was for previous SSTI [113.5]) versus much higher rates if comorbidities were present. Incidence rates (per 1000 PYO) of chronic ulcers increased over time from 11.3 to 18.2 (
Conclusions UNASSIGNED
The epidemiology of SSTI in the United States is changing and the disease burden is increasing despite stabilization in overall incidence. These data can inform identification of priority populations who could benefit from targeted interventions.

Identifiants

pubmed: 38835497
doi: 10.1093/ofid/ofae267
pii: ofae267
pmc: PMC11146672
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofae267

Informations de copyright

© GSK 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. E. A., M. P., F. B., V. V., and M. S. are employed by and hold financial equities in GSK. D. D. is employed by GSK. M. C. was employed by GSK at the time of the study. These authors declare no other financial and non-financial relationships and activities.

Auteurs

Venanzio Vella (V)

Vaccine Epidemiology-Bacterial, GSK, Siena, Italy.

Dominique Derreumaux (D)

Real World Analytics, GSK, Wavre, Belgium.

Emmanuel Aris (E)

Real World Analytics, GSK, Wavre, Belgium.

Michele Pellegrini (M)

Vaccines Clinical Sciences, GSK, Siena, Italy.

Mario Contorni (M)

Early Bacterial Vaccine Program, GSK, Siena, Italy.

Michael Scherbakov (M)

Global Medical Affairs, GSK, Wavre, Belgium.

Fabio Bagnoli (F)

Infectious Diseases Research Unit, GSK, Siena, Italy.

Classifications MeSH